Effect of Perioperative Oral Rifaximin on Early Graft Dysfunction in Adult Living Donor Liver Transplant
Effect of Perioperative Oral Rifaximin on Early Graft Dysfunction in Adult Living Donor Liver Transplant: An Open Label Randomized Control Trial
Institute of Liver and Biliary Sciences, India
100 participants
Dec 1, 2024
INTERVENTIONAL
Conditions
Summary
Liver transplantation has been a lifesaving treatment for individuals with end stage liver disease and acute liver failure. However, initial poor function of a liver allograft after liver transplantation, termed early graft dysfunction (EGD), has been associated with increased allograft loss or mortality after transplantation. EGD in LDLT is multifactorial. Factors affecting EGD are GRWR, ischemia reperfusion injury, recipient metabolic demand, graft quality, graft inflow and outflow. Studies shows that the incidence of EGD is 15-38%. It is associated with increased allograft loss \& mortality. Rifaximin is an antibiotic that reduces EGD by 50% as shown by 2 studies but this study was done in DDLT setting and rifaximin was given in the pretransplant group. In this investigators will study the effect of perioperative oral rifaximin on early graft dysfunction in adult living donor liver transplant.
Eligibility
Inclusion Criteria1
- All recipients (adults) undergoing living donor liver transplant in ILBS.
Exclusion Criteria6
- Negative consent
- Hypersensitivity to Rifaximin
- Patients undergoing retransplant
- ALF, ACLF
- Pediatrics patients
- Patients on rifaximin
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Preoperative Rifaximin supplementation 550 mg twice daily from preoperatively 2 weeks to post op POD 1 to 7
SOC means Standard of care which means that the patient will revieve standard post op care followed at our insitute and other hospitals in India.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06743464